Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$20.5 million.

  • aTYR PHARMA's Free Cash Flow fell 5572.0% to -$20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.0 million, marking a year-over-year increase of 612.91%. This contributed to the annual value of -$69.2 million for FY2024, which is 8480.61% down from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Free Cash Flow is -$20.5 million, which was down 5572.0% from -$13.9 million recorded in Q2 2025.
  • aTYR PHARMA's Free Cash Flow's 5-year high stood at -$1.8 million during Q1 2023, with a 5-year trough of -$22.4 million in Q1 2024.
  • Its 5-year average for Free Cash Flow is -$12.3 million, with a median of -$11.5 million in 2021.
  • As far as peak fluctuations go, aTYR PHARMA's Free Cash Flow surged by 8193.27% in 2023, and later tumbled by 111988.02% in 2024.
  • Over the past 5 years, aTYR PHARMA's Free Cash Flow (Quarter) stood at -$8.1 million in 2021, then plummeted by 41.76% to -$11.5 million in 2022, then grew by 3.56% to -$11.1 million in 2023, then fell by 18.76% to -$13.2 million in 2024, then tumbled by 55.91% to -$20.5 million in 2025.
  • Its Free Cash Flow stands at -$20.5 million for Q3 2025, versus -$13.9 million for Q2 2025 and -$15.4 million for Q1 2025.